Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Multinational Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including PI, IMID, and CD38 Monoclonal Antibody Treatment

Next Previous
Trial Profile

A Prospective, Multinational Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including PI, IMID, and CD38 Monoclonal Antibody Treatment

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Teclistamab (Primary) ; Antineoplastics
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms LocoMMotion
  • Sponsors Janssen-Cilag

Most Recent Events

  • 12 Dec 2023 Results of pooled analysis from LocoMMotion and other study , describing current treatment and outcomes in Patients with triple-class exposed RRMM with EMD over the past 3 years, presented at the 65th American Society of Hematology Annual Meeting and Exposition
  • 15 Jun 2023 Results presented at the 28th Congress of the European Haematology Association
  • 15 Jun 2023 Results of Comparative Effectiveness of Talquetamab (from MonumenTAL-1) vs Real-World Physicians Choice of Treatment in Locommotion and Momment for Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma , presented at the 28th Congress of the European Haematology Association

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top